Delving into the Latest Updates on DPA-BSTPG with Synapse

Overview

Basic Info

Drug Type

Drug conjugates

Synonyms-

Target

TSPO

Mechanism

TSPO modulators(Translocator protein modulators)

Therapeutic Areas

NeoplasmsNervous System Diseases

Active Indication-

Inactive Indication

Glioma

Originator Organization

Stella Pharma Corp.

Active Organization-

Inactive Organization

Stella Pharma Corp.

Drug Highest PhasePendingPreclinical

First Approval Date-

Regulation-

Structure

Boost your research with our ADC technology data.

login

or

view full example data

Boost your research with our ADC technology data.

Author: Takata, Takushi ; Takami, Toshihiro ; Kayama, Ryo ; Kirihata, Mitsunori ; Suzuki, Minoru ; Hiramatsu, Ryo ; Tanaka, Hiroki ; Shiba, Hiroyuki ; Yoshimura, Kohei ; Kashiwagi, Hideki ; Hattori, Yoshihide ; Kanemitsu, Takuya ; Hu, Naonori ; Kawabata, Shinji ; Watanabe, Tsubasa ; Fukuo, Yusuke ; Miyatake, Shin-Ichi ; Wanibuchi, Masahiko

Background: Boron neutron capture therapy (BNCT) has been adapted to high-grade gliomas (HG); however, some gliomas are refractory to BNCT using boronophenylalanine (BPA). In this study, the feasibility of BNCT targeting the 18 kDa translocator protein (TSPO) expressed in glioblastoma and surrounding environmental cells was investigated. Methods: Three rat glioma cell lines, an F98 rat glioma bearing brain tumor model, DPA-BSTPG which is a boron-10 compound targeting TSPO, BPA, and sodium borocaptate (BSH) were used. TSPO expression was evaluated in the F98 rat glioma model. Boron uptake was assessed in three rat glioma cell lines and in the F98 rat glioma model. In vitro and in vivo neutron irradiation experiments were performed. Results: DPA-BSTPG was efficiently taken up in vitro. The brain tumor has 16-fold higher TSPO expressions than its brain tissue. The compound biological effectiveness value of DPA-BSTPG was 8.43 to F98 rat glioma cells. The boron concentration in the tumor using DPA-BSTPG convection-enhanced delivery (CED) administration was approximately twice as high as using BPA intravenous administration. BNCT using DPA-BSTPG has significant efficacy over the untreated group. BNCT using a combination of BPA and DPA-BSTPG gained significantly longer survival times than using BPA alone. Conclusion: DPA-BSTPG in combination with BPA may provide the multi-targeted neutron capture therapy against HG.

100 Deals associated with DPA-BSTPG

Login to view more data